miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4

Liu,Xiaowu; Kong,Chuize; Zhang,Zhe

doi:10.3892/or.2018.6300

miR-130b promotes bladder cancer cell proliferation, migration and invasion by targeting VGLL4

Authors:
- Xiaowu Liu
- Chuize Kong
- Zhe Zhang
View Affiliations

Affiliations: Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: March 6, 2018 https://doi.org/10.3892/or.2018.6300
Pages: 2324-2332

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bladder cancer (BCa) is the most common urological cancer, and more and more evidence suggests that microRNAs (miRNAs) play an important role in BCa pathogenesis. Aberrant miR-130b expression has been reported in several types of cancers. The aim of the present study was to elucidate the effects of miR-130b on BCa progression. miR‑130b expression in BCa cell lines and tissues was detected using real-time PCR (RT-PCR), and vestigial-like protein 4 (VGLL4) expression in tissue specimens and BCa cells that had been transfected with miR-130b mimics and inhibitors was detected using western blotting. Dual-luciferase reporter assay was performed to confirm whether the VGLL4 gene is a direct target of miR-130b, and in vitro cell function testing, Cell Counting Kit-8 (CCK-8) assay, colony formation assay, wound healing and Transwell assays were performed to examine BCa cell proliferation, migration and invasion ability after the cells were transfected with miR-130b mimics and inhibitors and VGLL4 siRNA. miR-130b was found to be upregulated in BCa cells and tissues. miR-130b overexpression promoted BCa cell proliferation, migration and invasion, whereas miR-130b inhibition had the opposite effects. Dual-luciferase reporter assay confirmed that the VGLL4 gene was a direct target of miR-130b and that VGLL4 suppression was crucial for miR‑130b-induced BCa cell proliferation, migration and invasion. The present study showed that miR-130b was significantly upregulated in BCa and may play an oncogenic role in BCa occurrence and development by targeting VGLL4. miR-130b may be a potential therapeutic target in the treatment of BCa.

View Figures

View References

1	Acloque H, Thiery JP and Nieto MA: The physiology and pathology of the EMT. Meeting on the epithelial-mesenchymal transition. EMBO Rep. 9:322–326. 2008. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Luke C, Tracey E, Stapleton A and Roder D: Exploring contrary trends in bladder cancer incidence, mortality and survival: Implications for research and cancer control. Intern Med J. 40:357–362. 2010. View Article : Google Scholar : PubMed/NCBI
4	van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009. View Article : Google Scholar : PubMed/NCBI
5	Tan YG, Eu E, Kam Lau On W and Huang HH: Pretreatment neutrophil-to-lymphocyte ratio predicts worse survival outcomes and advanced tumor staging in patients undergoing radical cystectomy for bladder cancer. Asian J Urol. 4:239–246. 2017. View Article : Google Scholar : PubMed/NCBI
6	Urquidi V, Netherton M, Gomes-Giacoia E, Serie DJ, Eckel-Passow J, Rosser CJ and Goodison S: A microRNA biomarker panel for the non-invasive detection of bladder cancer. Oncotarget. 7:86290–86299. 2016. View Article : Google Scholar : PubMed/NCBI
7	Falzone L, Candido S, Salemi R, Basile MS, Scalisi A, McCubrey JA, Torino F, Signorelli SS, Montella M and Libra M: Computational identification of microRNAs associated to both epithelial to mesenchymal transition and NGAL/MMP-9 pathways in bladder cancer. Oncotarget. 7:72758–72766. 2016. View Article : Google Scholar : PubMed/NCBI
8	Amir S and Mabjeesh NJ: microRNA expression profiles as decision-making biomarkers in the management of bladder cancer. Histol Histopathol. 32:107–119. 2017.PubMed/NCBI
9	Shin SS, Park SS, Hwang B, Moon B, Kim WT, Kim WJ and Moon SK: MicroRNA-892b influences proliferation, migration and invasion of bladder cancer cells by mediating the p19^ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways. Oncol Rep. 36:2313–2320. 2016. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
11	Wang D, Qiu C, Zhang H, Wang J, Cui Q and Yin Y: Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: From functions to targets. PLoS One. 5:52010.
12	Tang J, Ahmad A and Sarkar FH: The role of microRNAs in breast cancer migration, invasion and metastasis. Int J Mol Sci. 13:13414–13437. 2012. View Article : Google Scholar : PubMed/NCBI
13	Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du Y, Luo X, Zheng F, Liu R, Zhang H, et al: miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10. BMC Cancer. 12:1112012. View Article : Google Scholar : PubMed/NCBI
14	Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C and McConkey DJ: Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. 7:80164–80174. 2016. View Article : Google Scholar : PubMed/NCBI
15	Burmistrova OA, Goltsov AY, Abramova LI, Kaleda VG, Orlova VA and Rogaev EI: MicroRNA in schizophrenia: Genetic and expression analysis of miR-130b (22q11). Biochemistry. 72:578–582. 2007.PubMed/NCBI
16	Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, et al: Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI
17	Chang RM, Xu JF, Fang F, Yang H and Yang LY: MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling. Tumour Biol. 37:10609–10619. 2016. View Article : Google Scholar : PubMed/NCBI
18	Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stühler K, Meyer HE and Reifenberger G: Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 20:539–550. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE and Nikiforova MN: MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 18:2035–2041. 2011. View Article : Google Scholar : PubMed/NCBI
20	Dong P, Karaayvaz M, Jia N, Kaneuchi M, Hamada J, Watari H, Sudo S, Ju J and Sakuragi N: Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 32:3286–3295. 2013. View Article : Google Scholar : PubMed/NCBI
21	Chen Q, Zhao X, Zhang H, Yuan H, Zhu M, Sun Q, Lai X, Wang Y, Huang J, Yan J, et al: MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2. Mol Carcinog. 54:1292–1300. 2015. View Article : Google Scholar : PubMed/NCBI
22	Gabriel BM, Hamilton DL, Tremblay AM and Wackerhage H: The Hippo signal transduction network for exercise physiologists. J Appl Physiol 1985. 120:1105–1117. 2016. View Article : Google Scholar : PubMed/NCBI
23	Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, et al: A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 25:166–180. 2014. View Article : Google Scholar : PubMed/NCBI
24	Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE and Dupuy AJ: Australian Pancreatic Cancer Genome Initiative, Chang DK, Biankin AV, Waddell N, Kassahn KS, Grimmond SM, Rust AG, Adams DJ, Jenkins NA and Copeland NG: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 109:5934–5941. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z, et al: VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res. 24:331–343. 2014. View Article : Google Scholar : PubMed/NCBI
26	Jiang W, Yao F and He J, Lv B, Fang W, Zhu W, He G, Chen J and He J: Downregulation of VGLL4 in the progression of esophageal squamous cell carcinoma. Tumour Biol. 36:1289–1297. 2015. View Article : Google Scholar : PubMed/NCBI
27	Li H, Wang Z, Zhang W, Qian K, Liao G, Xu W and Zhang S: VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer. Med Oncol. 32:832015. View Article : Google Scholar : PubMed/NCBI
28	Li N, Yu N, Wang J, Xi H, Lu W, Xu H, Deng M, Zheng G and Liu H: miR-222/VGLL4/YAP-TEAD1 regulatory loop promotes proliferation and invasion of gastric cancer cells. Am J Cancer Res. 5:1158–1168. 2015.PubMed/NCBI
29	Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M and Enokida H: Aberrant expression of microRNAs in bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
30	Bibi F, Naseer MI, Alvi SA, Yasir M, Jiman-Fatani AA, Sawan A, Abuzenadah AM, Al-Qahtani MH and Azhar EI: microRNA analysis of gastric cancer patients from Saudi Arabian population. BMC Genomics. 17 Suppl 9:S7512016. View Article : Google Scholar
31	Li M, Li J, Ding X, He M and Cheng SY: microRNA and cancer. AAPS J. 12:309–317. 2010. View Article : Google Scholar : PubMed/NCBI
32	Cheng Y, Zhang X and Li P, Yang C, Tang J, Deng X, Yang X, Tao J, Lu Q and Li P: MiR-200c promotes bladder cancer cell migration and invasion by directly targeting RECK. Onco Targets Ther. 9:5091–5099. 2016. View Article : Google Scholar : PubMed/NCBI
33	Huang B, Zhai W, Hu G, Huang C, Xie T, Zhang J and Xu Y: MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC. Am J Transl Res. 8:4705–4715. 2016.PubMed/NCBI
34	Pospisilova S, Pazourkova E, Horinek A, Brisuda A, Svobodova I, Soukup V, Hrbacek J, Capoun O, Hanus T, Mares J, et al: MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. Neoplasma. 63:799–808. 2016. View Article : Google Scholar : PubMed/NCBI
35	Koontz LM, Liu-Chittenden Y, Yin F, Zheng Y, Yu J, Huang B, Chen Q, Wu S and Pan D: The Hippo effector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression. Dev Cell. 25:388–401. 2013. View Article : Google Scholar : PubMed/NCBI
36	Dong L, Lin F, Wu W, Huang W and Cai Z: Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell. J Cancer. 7:2132–2138. 2016. View Article : Google Scholar : PubMed/NCBI
37	Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R, et al: Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med. 115:447–457. 2018. View Article : Google Scholar : PubMed/NCBI